Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2012
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of two formulations of GSK Biologicals\' pneumococcal vaccine (2830929A and 2830930A) administered as 3-dose primary vaccination during the first 6 months of life followed by a booster dose in the second year of life. To comply with the routine infant immunisation program, the licensed GSK Biologicals DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine will be co-administered in infants with the pneumococcal study vaccines.
Epistemonikos ID: c4515dbf1dc19dccf50f03bb44f7d1b49a23e05b
First added on: Nov 24, 2021